Anti-drug antibodies to LMB-100 are enhanced by mAbs targeting OX40 and CTLA4 but not by mAbs targeting PD1 or PDL-1.
Anti-drug antibodies to LMB-100 are enhanced by mAbs targeting OX40 and CTLA4 but not by mAbs targeting PD1 or PDL-1.
复制标题
DOI：
10.1016/j.cellimm.2018.08.016
复制
发表时间：
2018-12
影响因子：
4.3
通讯作者：
Pastan I
中科院分区：
文献类型：
--
作者：
Mazor R;King E;Pastan I
LMB-100 is a recombinant immunotoxin being developed for cancer treatment that is composed of a Fab that binds to mesothelin and a portion of Pseudomonas exotoxin A. LMB-100 is in clinical trials for the treatment of mesothelioma and pancreatic cancer. To determine if check point modulating antibodies enhance the formation of anti-drug antibodies (ADA) against LMB-100, we treated mice with LMB-100 and four different immune modulating monoclonal antibodies that have different mechanisms of action; anti-CTLA4, anti-OX40, anti-PD-1 and anti-PDL-1. We found that anti-PD-1 and anti PDL-1 do not increase the formation of ADA, but anti-CTLA-4 and anti-OX-40 do increase the onset of ADA. These results indicate that combining anti-CTLA-4 and anti-OX-40 with antibodies and other protein-based therapeutics may enhance ADA formation in humans.
登录
查看更多内容
DOI：
10.1158/1078-0432.ccr-14-1339
发表时间：
2015-03-01
期刊：
Clinical cancer research : an official journal of the American Association for Cancer Research
影响因子：
--
作者：
Dai M;Yip YY;Hellstrom I;Hellstrom KE
通讯作者：
Hellstrom KE
影响因子：
24.1
作者：
Mazor, Ronit;Crown, Devorah;Pastan, Ira
通讯作者：
Pastan, Ira
影响因子：
10.1
作者：
Mueller, Philipp;Martin, Kea;Zippelius, Alfred
通讯作者：
Zippelius, Alfred
影响因子：
10.1
作者：
Leshem Y;O'Brien J;Liu X;Bera TK;Terabe M;Berzofsky JA;Bossenmaier B;Niederfellner G;Tai CH;Reiter Y;Pastan I
通讯作者：
Pastan I
影响因子：
28.4
作者：
Johnson, Douglas B.;Sullivan, Ryan J.;Clark, Joseph I.
通讯作者：
Clark, Joseph I.